Technical Analysis for URGN - UroGen Pharma Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 6.25% | |
| Earnings Movers | Other | 6.25% | |
| Inside Day | Range Contraction | 6.25% | |
| Gapped Down | Weakness | 6.25% | |
| Lower Bollinger Band Touch | Weakness | 6.25% | |
| Slingshot Bearish | Bearish Swing Setup | 5.43% | |
| Bullish Engulfing | Bullish | 5.43% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 17 hours ago |
| Up 1 ATR | about 22 hours ago |
| 20 DMA Resistance | about 22 hours ago |
| Rose Above 20 DMA | about 22 hours ago |
| 2x Volume Pace | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.13 |
| 52 Week Low | 8.69 |
| Average Volume | 354,723 |
| 200-Day Moving Average | 15.27 |
| 50-Day Moving Average | 14.58 |
| 20-Day Moving Average | 13.80 |
| 10-Day Moving Average | 13.47 |
| Average True Range | 0.95 |
| RSI (14) | 48.72 |
| ADX | 17.96 |
| +DI | 17.43 |
| -DI | 29.67 |
| Chandelier Exit (Long, 3 ATRs) | 12.22 |
| Chandelier Exit (Short, 3 ATRs) | 13.44 |
| Upper Bollinger Bands | 14.87 |
| Lower Bollinger Band | 12.73 |
| Percent B (%b) | 0.49 |
| BandWidth | 15.45 |
| MACD Line | -0.39 |
| MACD Signal Line | -0.38 |
| MACD Histogram | -0.0074 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.16 | ||||
| Resistance 3 (R3) | 15.10 | 14.57 | 14.93 | ||
| Resistance 2 (R2) | 14.57 | 14.22 | 14.61 | 14.85 | |
| Resistance 1 (R1) | 14.18 | 14.00 | 14.38 | 14.24 | 14.78 |
| Pivot Point | 13.65 | 13.65 | 13.75 | 13.69 | 13.65 |
| Support 1 (S1) | 13.26 | 13.30 | 13.46 | 13.32 | 12.78 |
| Support 2 (S2) | 12.73 | 13.08 | 12.77 | 12.71 | |
| Support 3 (S3) | 12.34 | 12.73 | 12.63 | ||
| Support 4 (S4) | 12.40 |
